Cardiovascular Research at Penn

Cardiovascular disease clinical trials and research studies are at enrolling Penn Medicine.

New and Promising Treatments for Patients with Heart Disease

Clinical trials at the Penn Cardiovascular Institute in Philadelphia can offer new and promising treatments for patients with heart disease. Penn clinicians and scientists are finding novel ways to treat cardiovascular conditions by researching the latest medications, devices and procedures. These cardiovascular clinical studies are performed collaboratively with scientists and clinicians throughout the University of Pennsylvania and Penn Medicine.

Browse Cardiovascular Clinical Trials by Common Topics

For general questions about cardiovascular clinical trials at Penn, email or call 215-746-4946.

Reasons to Participate in a Clinical Trial

There are a number of reasons why patients enroll in clinical trials and clinical research studies.

  • Patients can gain access to new experimental drugs or treatments
  • Patients are interested in having a more active role in his or her healthcare
  • Patients are interested in advancing science and medical care

By participating in clinical trials, participants help advance what is known about medical interventions. In doing so, clinical trial participants can play an important role in getting new drugs and devices approved for use in treating other patients.

National and International Cardiovascular Patient Registries

National and international patient registries enable researchers and physicians to collect, analyze and interpret data about specific diseases and conditions.

Penn Cardiovascular Institute researchers are involved with two patient registries:

GenTAC: National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions

GenTAC is a national registry of patients with genetic conditions that may be related to thoracic aortic aneurysms. The information collected through the registry will help doctors and researchers better understand the link between genes and aortic aneurysms and heart disease. GenTAC also enables research to determine the best ways to manage the complications of cardiovascular disease that can arise from some genetic disorders. Better understanding and more research will lead to better treatment. Samples and data are made available to qualified investigators to enable research to determine best medical practices and to advance the clinical management of genetic thoracic aortic aneurysms, and other cardiovascular complications.

The registry is sponsored by the National Heart, Lung, and Blood Institute and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Contact To Enroll:
Amber Ashley Parker

Penn Investigator for GenTAC

Joseph E. Bavaria, MD, professor of surgery and the director of the Thoracic Aortic Surgery Program. His clinical interests involve complex aortic diseases, cardiopulmonary transplantation, and cardiac valve surgery. Dr. Bavaria has published extensively on issues regarding thoracic aortic surgery, lung transplantation, and circulation management for complex thoracic aortic reconstruction.

Visit the GenTAC website for more information

IRAD: International Registry of Acute Aortic Dissections

IRAD, or the International Registry of Acute Aortic Dissection, is a consortium of research centers that are evaluating the current management and outcomes of acute aortic dissection.  Established in 1996, IRAD currently has 24 large referral centers in 12 countries, including the University of Pennsylvania.  To date, more than 1,300 patients have been enrolled. This registry enrolls people who unfortunately have suffered a sudden tear in the wall of their aorta. Everything from dates and times of symptom onset, presentation, diagnosis, hemodynamic signs of aortic dissection, initial and chronic medical therapy, diagnostic imaging chosen, and surgical and medical management is being collected and studied.  Data collection occurs while the patient is in the hospital through discharge, and recently, IRAD began collecting 5 year longitudinal data to look at long term outcomes of this patient population. The goal of the IRAD study is to assess changes in presentation, diagnosis, management, and outcomes of patients that present with aortic dissections.  Valuable research is being done with this data that will help improve the care that patients receive when a diagnosis like this is made.

Contact to Enroll
Alison Toback, MPH

Penn Investigator for IRAD

Reed Pyeritz, MD, PhD, director of the Penn Center for Integration of Genetic and Healthcare Technologies (Penn CIGHT). Dr. Pyeritz has long been recognized as an international authority on the genetics of cardiovascular disorders, especially the Marfan syndrome and hereditary hemorrhagic telangiectasia.

Visit the IRAD website for more information


For general questions about cardiovascular clinical trials at Penn, email or call 215-746-4946.

Share This Page: